1707 related articles for article (PubMed ID: 31465532)
61. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
62. [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].
Zuo YX; Jia YP; Wu J; Wang JB; Lu AD; Dong LJ; Chang LJ; Zhang LP
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):270-275. PubMed ID: 31104436
[No Abstract] [Full Text] [Related]
63. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
Tan Y; Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Yu X; Chang AH; Feng X
Cancer Immunol Immunother; 2021 Jul; 70(7):1979-1993. PubMed ID: 33416942
[TBL] [Abstract][Full Text] [Related]
64. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
65. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Pan J; Niu Q; Deng B; Liu S; Wu T; Gao Z; Liu Z; Zhang Y; Qu X; Zhang Y; Liu S; Ling Z; Lin Y; Zhao Y; Song Y; Tan X; Zhang Y; Li Z; Yin Z; Chen B; Yu X; Yan J; Zheng Q; Zhou X; Gao J; Chang AH; Feng X; Tong C
Leukemia; 2019 Dec; 33(12):2854-2866. PubMed ID: 31110217
[TBL] [Abstract][Full Text] [Related]
66. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
67. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
68. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Geyer MB; Manjunath SH; Evans AG; Park JH; Davila ML; Cutler CS; Wang X; Wang Y; Senechal B; Rivière I; Sadelain M; Liesveld JL; Brentjens RJ
Leuk Lymphoma; 2018 Jul; 59(7):1717-1721. PubMed ID: 29043880
[No Abstract] [Full Text] [Related]
69. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
Wang T; Tang Y; Cai J; Wan X; Hu S; Lu X; Xie Z; Qiao X; Jiang H; Shao J; Yang F; Ren H; Cao Q; Qian J; Zhang J; An K; Wang J; Luo C; Liang H; Miao Y; Ma Y; Wang X; Ding L; Song L; He H; Shi W; Xiao P; Yang X; Yang J; Li W; Zhu Y; Wang N; Gu L; Chen Q; Tang J; Yang JJ; Cheng C; Leung W; Chen J; Lu J; Li B; Pui CH
J Clin Oncol; 2023 Mar; 41(9):1670-1683. PubMed ID: 36346962
[TBL] [Abstract][Full Text] [Related]
70. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Elsallab M; Ellithi M; Hempel S; Abdel-Azim H; Abou-El-Enein M
Cancer Gene Ther; 2023 Jun; 30(6):845-854. PubMed ID: 36750666
[TBL] [Abstract][Full Text] [Related]
71. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
72. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
Zanetti SR; Romecin PA; Vinyoles M; Juan M; Fuster JL; Cámos M; Querol S; Delgado M; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868394
[TBL] [Abstract][Full Text] [Related]
73. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
74. Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
Jacoby E; Bielorai B; Hutt D; Itzhaki O; Adam E; Bar D; Besser MJ; Toren A
Br J Haematol; 2022 May; 197(4):475-481. PubMed ID: 35224724
[TBL] [Abstract][Full Text] [Related]
75. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
76. [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].
Wang SY; Zhao LN; Cheng H; Shi M; Chen W; Qi KM; Sun C; Wang X; Cao J; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):557-561. PubMed ID: 36709132
[No Abstract] [Full Text] [Related]
77. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
[TBL] [Abstract][Full Text] [Related]
78. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
Front Immunol; 2019; 10():2664. PubMed ID: 31798590
[TBL] [Abstract][Full Text] [Related]
79. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
80. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
